NASDAQ:CDMO Avid Bioservices (CDMO) Stock Forecast, Price & News $15.09 -0.12 (-0.79%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$14.95▼$15.4650-Day Range$14.59▼$20.9352-Week Range$11.34▼$21.05Volume482,723 shsAverage Volume440,290 shsMarket Capitalization$943.88 millionP/E Ratio9.09Dividend YieldN/APrice Target$22.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Avid Bioservices MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside48.0% Upside$22.33 Price TargetShort InterestBearish9.66% of Shares Sold ShortDividend StrengthN/ASustainability-0.96Upright™ Environmental ScoreNews Sentiment0.45Based on 2 Articles This WeekInsider TradingSelling Shares$1.31 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector430th out of 1,018 stocksPharmaceutical Preparations Industry195th out of 498 stocks 3.5 Analyst's Opinion Consensus RatingAvid Bioservices has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.33, Avid Bioservices has a forecasted upside of 48.0% from its current price of $15.09.Amount of Analyst CoverageAvid Bioservices has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.66% of the outstanding shares of Avid Bioservices have been sold short.Short Interest Ratio / Days to CoverAvid Bioservices has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Avid Bioservices has recently increased by 14.83%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvid Bioservices does not currently pay a dividend.Dividend GrowthAvid Bioservices does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAvid Bioservices has received a 68.99% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Biopharmaceuticals", "Clinical research services", and "Process engineering services for the pharmaceutical industry" products. See details.Environmental SustainabilityThe Environmental Impact score for Avid Bioservices is -0.96. Previous Next 1.9 News and Social Media Coverage News SentimentAvid Bioservices has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Avid Bioservices this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added Avid Bioservices to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avid Bioservices insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,310,050.00 in company stock.Percentage Held by InsidersOnly 1.86% of the stock of Avid Bioservices is held by insiders.Percentage Held by Institutions98.95% of the stock of Avid Bioservices is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Avid Bioservices is 9.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.84.Price to Earnings Ratio vs. SectorThe P/E ratio of Avid Bioservices is 9.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 132.90.Price to Book Value per Share RatioAvid Bioservices has a P/B Ratio of 5.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Avid Bioservices (NASDAQ:CDMO) StockAvid Bioservices, Inc. engages in the commercial manufacturing. The firm focuses on the biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. It specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions and support. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.Read More Receive CDMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter. Email Address CDMO Stock News HeadlinesMay 19, 2023 | americanbankingnews.comAvid Bioservices (NASDAQ:CDMO) Stock Price Down 4.4%May 5, 2023 | americanbankingnews.comInsider Selling: Avid Bioservices, Inc. (NASDAQ:CDMO) General Counsel Sells $447,750.00 in StockMay 27, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Develops World's First Anti-Aircraft LaserSmall cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>May 4, 2023 | americanbankingnews.comShort Interest in Avid Bioservices, Inc. (NASDAQ:CDMO) Grows By 5.4%May 3, 2023 | benzinga.comDirector at Avid Bioservices Exercises Options Worth $88KMay 3, 2023 | americanbankingnews.comAvid Bioservices, Inc. (NASDAQ:CDMO) Director Richard B. Hancock Sells 5,000 SharesApril 27, 2023 | msn.comIqvia, Icon lag contract research rivals after Q1 earningsApril 24, 2023 | finance.yahoo.comAvid Bioservices Joins Elite Club Of Stocks With RS Ratings Over 90May 27, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!April 17, 2023 | finance.yahoo.comImproved Earnings Required Before Avid Bioservices, Inc. (NASDAQ:CDMO) Shares Find Their FeetApril 17, 2023 | americanbankingnews.comInsider Selling: Avid Bioservices, Inc. (NASDAQ:CDMO) CEO Sells $146,440.00 in StockApril 15, 2023 | americanbankingnews.comInsider Selling: Avid Bioservices, Inc. (NASDAQ:CDMO) Director Sells $141,902.64 in StockApril 14, 2023 | americanbankingnews.comInsider Selling: Avid Bioservices, Inc. (NASDAQ:CDMO) CFO Sells $25,344.00 in StockApril 14, 2023 | americanbankingnews.comAvid Bioservices, Inc. (NASDAQ:CDMO) CEO Nicholas Stewart Green Sells 7,598 SharesApril 13, 2023 | americanbankingnews.comMark R. Ziebell Sells 736 Shares of Avid Bioservices, Inc. (NASDAQ:CDMO) StockApril 8, 2023 | americanbankingnews.comDaniel R. Hart Sells 1,250 Shares of Avid Bioservices, Inc. (NASDAQ:CDMO) StockApril 6, 2023 | americanbankingnews.comAvid Bioservices, Inc. (NASDAQ:CDMO) Director Richard B. Hancock Sells 5,000 Shares of StockApril 4, 2023 | finance.yahoo.comAvid Bioservices Unveils Completed Mammalian Cell Facilities Expansion Providing Significantly Increased Capacity for Existing and Future CustomersMarch 14, 2023 | msn.comKeybanc Upgrades Avid Bioservices (CDMO)March 14, 2023 | benzinga.comAvid Bioservices shares are trading higher after the company reported better-than-expected Q3 adjusted EPS and sales results.March 14, 2023 | marketwatch.comAvid Bioservices Shares Soar on 3Q ResultsMarch 14, 2023 | finance.yahoo.comAvid Bioservices, Inc. (NASDAQ:CDMO) Q3 2023 Earnings Call TranscriptMarch 14, 2023 | finance.yahoo.comWhy Avid Bioservices Stock Is Surging TodayMarch 14, 2023 | finance.yahoo.comQ3 2023 Avid Bioservices Inc Earnings CallMarch 14, 2023 | finance.yahoo.comDeclining Stock and Solid Fundamentals: Is The Market Wrong About Avid Bioservices, Inc. (NASDAQ:CDMO)?March 10, 2023 | finance.yahoo.comSteer Clear Of These 4 Toxic Stocks to Avoid LossesMarch 6, 2023 | finance.yahoo.comAvid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2023 After Market Close on March 13, 2023See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CDMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter. Email Address CDMO Company Calendar Last Earnings3/13/2023Today5/27/2023Next Earnings (Estimated)7/05/2023Fiscal Year End4/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CDMO CUSIPN/A CIK704562 Webwww.avidbio.com Phone(714) 508-6100Fax714-838-5817Employees252Year FoundedN/APrice Target and Rating Average Stock Price Forecast$22.33 High Stock Price Forecast$25.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+48.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$1.66 Trailing P/E Ratio9.09 Forward P/E RatioN/A P/E GrowthN/ANet Income$127.67 million Net Margins82.78% Pretax Margin1.52% Return on Equity1.70% Return on Assets0.69% Debt Debt-to-Equity Ratio0.77 Current Ratio1.52 Quick Ratio1.00 Sales & Book Value Annual Sales$119.60 million Price / Sales7.89 Cash Flow$0.36 per share Price / Cash Flow42.02 Book Value$2.83 per share Price / Book5.33Miscellaneous Outstanding Shares62,550,000Free Float61,384,000Market Cap$943.88 million OptionableOptionable Beta1.82 Key ExecutivesNicholas S. GreenPresident, Chief Executive Officer & DirectorRichard A. RichieriChief Operating OfficerDaniel Ryan HartChief Financial OfficerNick FergusonExecutive Director-Information TechnologyMark R. ZiebellSecretary, Vice President & General CounselKey CompetitorsKiniksa PharmaceuticalsNASDAQ:KNSADay One BiopharmaceuticalsNASDAQ:DAWNKura OncologyNASDAQ:KURAInnovivaNASDAQ:INVAStructure TherapeuticsNASDAQ:GPCRView All CompetitorsInsiders & InstitutionsLegato Capital Management LLCSold 19,520 shares on 5/25/2023Ownership: 0.061%Ameriprise Financial Inc.Sold 6,898 shares on 5/22/2023Ownership: 0.536%New York State Common Retirement FundBought 59,342 shares on 5/18/2023Ownership: 1.345%JPMorgan Chase & Co.Bought 8,065 shares on 5/18/2023Ownership: 0.125%Thrivent Financial for LutheransSold 2,019 shares on 5/17/2023Ownership: 0.099%View All Insider TransactionsView All Institutional Transactions CDMO Stock - Frequently Asked Questions Should I buy or sell Avid Bioservices stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CDMO shares. View CDMO analyst ratings or view top-rated stocks. What is Avid Bioservices' stock price forecast for 2023? 2 analysts have issued 12-month price objectives for Avid Bioservices' shares. Their CDMO share price forecasts range from $20.00 to $25.00. On average, they predict the company's share price to reach $22.33 in the next twelve months. This suggests a possible upside of 48.0% from the stock's current price. View analysts price targets for CDMO or view top-rated stocks among Wall Street analysts. How have CDMO shares performed in 2023? Avid Bioservices' stock was trading at $13.77 at the beginning of 2023. Since then, CDMO stock has increased by 9.6% and is now trading at $15.09. View the best growth stocks for 2023 here. Are investors shorting Avid Bioservices? Avid Bioservices saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 6,040,000 shares, an increase of 14.8% from the April 30th total of 5,260,000 shares. Based on an average trading volume of 593,500 shares, the days-to-cover ratio is currently 10.2 days. View Avid Bioservices' Short Interest. When is Avid Bioservices' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 5th 2023. View our CDMO earnings forecast. How were Avid Bioservices' earnings last quarter? Avid Bioservices, Inc. (NASDAQ:CDMO) issued its earnings results on Monday, March, 13th. The biopharmaceutical company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.11. The biopharmaceutical company had revenue of $38.02 million for the quarter, compared to analyst estimates of $36 million. Avid Bioservices had a trailing twelve-month return on equity of 1.70% and a net margin of 82.78%. What ETFs hold Avid Bioservices' stock? ETFs with the largest weight of Avid Bioservices (NASDAQ:CDMO) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), Franklin Genomic Advancements ETF (HELX), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), iShares Micro-Cap ETF (IWC), Syntax Stratified SmallCap ETF (SSLY) and Xtrackers S&P SmallCap 600 ESG ETF (SMLE). When did Avid Bioservices' stock split? Avid Bioservices's stock reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What guidance has Avid Bioservices issued on next quarter's earnings? Avid Bioservices issued an update on its FY 2023 earnings guidance on Monday, March, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $145.00 million-$150.00 million, compared to the consensus revenue estimate of $146.57 million. What is Roger Lias' approval rating as Avid Bioservices' CEO? 5 employees have rated Avid Bioservices Chief Executive Officer Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among the company's employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 63.0% of employees surveyed would recommend working at Avid Bioservices to a friend. What other stocks do shareholders of Avid Bioservices own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE). What is Avid Bioservices' stock symbol? Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO." Who are Avid Bioservices' major shareholders? Avid Bioservices' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.53%), State Street Corp (5.98%), Jennison Associates LLC (4.70%), Ranger Investment Management L.P. (3.63%), FMR LLC (3.60%) and Snyder Capital Management L P (2.76%). Insiders that own company stock include Daniel R Hart, Gregory Sargen, Mark R Bamforth, Mark R Ziebell, Nicholas Stewart Green and Richard B Hancock. View institutional ownership trends. How do I buy shares of Avid Bioservices? Shares of CDMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Avid Bioservices' stock price today? One share of CDMO stock can currently be purchased for approximately $15.09. How much money does Avid Bioservices make? Avid Bioservices (NASDAQ:CDMO) has a market capitalization of $943.88 million and generates $119.60 million in revenue each year. The biopharmaceutical company earns $127.67 million in net income (profit) each year or $1.66 on an earnings per share basis. How many employees does Avid Bioservices have? The company employs 252 workers across the globe. How can I contact Avid Bioservices? Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The official website for the company is www.avidbio.com. The biopharmaceutical company can be reached via phone at (714) 508-6100, via email at sdiaz@vidasp.com, or via fax at 714-838-5817. This page (NASDAQ:CDMO) was last updated on 5/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avid Bioservices, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.